Quantcast
Last updated on April 24, 2014 at 5:01 EDT

Latest Omeprazole Stories

2008-08-12 03:00:18

By Anonymous United States of America - The Food and Drug Administration (FDA) has approved esomeprazole magnesium (Nexium(R)) for short-term use in children 1-11 years of age for the treatment of gastroesophageal reflux disease (GERD). The agency approved Nexium(R) in two forms, a delayed-release capsule and liquid form, in 10 mg or 20 mg daily for children 1-11 years old compared to 20 mg or 40 mg recommended for pediatric patients 12-17 years of age. Children prescribed this drug should...

2008-07-29 09:01:14

Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Laboratories, Gurgaon, India, has announced that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40mg capsules in the US healthcare system. Ranbaxy's Omeprazole 40mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. Jim Meehan, vice president of sales and distribution at Ranbaxy Pharmaceuticals, said: "We...

2008-07-28 12:01:07

GURGAON, India and PRINCETON, N.J., July 28 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), Gurgaon, India announced today that under an agreement with AstraZeneca Pharmaceuticals it has launched an authorized generic of Omeprazole 40 mg Capsules in the U.S. healthcare system. Omeprazole 40 mg is indicated for the treatment of acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. The most common...

2008-07-25 09:01:18

CORONA, Calif., July 25 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that its subsidiary has commenced commercial shipment of its Omeprazole Delayed-Release Capsules USP product in the 40mg strength from its Davie, Florida manufacturing facility. In conjunction with the launch, Watson has 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for the 40mg strength....

2008-06-18 12:00:11

Research and Markets (http://www.researchandmarkets.com/research/e40571/gastrointestinal_d) has announced the addition of the "Gastrointestinal Drug Discoveries: What the Future Holds" report to their offering. This new strategic report from Espicom provides a comprehensive review of current and future treatments for major gastrointestinal therapy areas: inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and gastro-oesophageal reflux disease (GORD). Inflammatory Bowel...

2008-06-16 09:01:20

Cogentus Pharmaceuticals has enrolled the first patient in Europe in the company's pivotal Phase III study of its novel combination medicine CGT-2168. The patient entered the Cogent-1 study at the Zadebie cardiology clinic in Skierniewice, Poland. The study, which began in North America in January, 2008 is evaluating the antiplatelet medicine CGT-2168, a combination of clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as Plavix) and a gastroprotectant (omeprazole)...

2008-06-16 09:00:10

MENLO PARK, Calif., June 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in Europe in the company's pivotal Phase 3 study of its novel combination medicine CGT-2168. The patient entered the COGENT-1 study at the Zadebie cardiology clinic in Skierniewice, Poland. (Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO) The study, which began in North America in January, is evaluating the antiplatelet medicine CGT-2168, a...

2008-03-12 09:01:05

ALLEGAN, Mich., March 12 /PRNewswire/ -- Beginning early March 2008, the nearly 30 million frequent heartburn sufferers nationwide will have a new treatment option available to them as retailers begin selling store brand Omeprazole, a proton pump inhibitor that will treat the same frequent heartburn symptoms as Prilosec OTC(R) at a significant cost savings for consumers. "It is estimated that consumers could save more than $100 million annually by using store brand Omeprazole," says Fred...

2005-12-20 09:04:21

CHICAGO (Reuters) - Popular anti-heartburn drugs such as proton-pump inhibitors that block stomach acid production heighten the risk of an increasingly common infectious form of diarrhea, researchers said on Monday. Taking such drugs as AstraZeneca's Nexium and Losec or their generic versions tripled the risk of diarrhea blamed on the Clostridium difficile bacteria, the study concluded. Frequently prescribed anti-heartburn drugs called H2 antagonists that include GlaxoSmithKline's...

2005-12-20 03:33:02

please read in second paragraph ... AstraZeneca's Nexium and Losec ... instead of ... AstraZeneca's Nexium and GlaxoSmithKline Plc's Losec. . A corrected repeat follows: CHICAGO (Reuters) - Popular anti-heartburn drugs such as proton-pump inhibitors that block stomach acid production heighten the risk of an increasingly common infectious form of diarrhea, researchers said on Monday. Taking such drugs as AstraZeneca's Nexium and Losec or their generic versions tripled the risk of...